Newtown, PA, United States of America

Oliver P Flint

This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2006.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oliver P Flint - Innovator in Toxicity Screening Methods

Introduction

Oliver P Flint is a notable inventor based in Newtown, PA (US). He has made significant contributions to the field of drug development, particularly in the area of toxicity screening for test compounds. His work is essential for ensuring the safety and efficacy of new drug candidates.

Latest Patents

Oliver P Flint holds 1 patent for his invention titled "Methods of screening for toxicity of test compounds." This patent relates to innovative methods for screening drug candidates for toxic effects on human cells. The invention provides valuable techniques for determining idiosyncratic toxicity of test compounds, which is crucial for the pharmaceutical industry.

Career Highlights

Oliver is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role involves research and development, focusing on creating safer and more effective drug candidates. His expertise in toxicity screening is vital for advancing drug safety protocols.

Collaborations

Oliver has collaborated with esteemed colleagues, including Stephen K Durham and Frederic Moulin. These partnerships enhance the research efforts at Bristol-Myers Squibb and contribute to the development of innovative solutions in drug safety.

Conclusion

In summary, Oliver P Flint is a dedicated inventor whose work in toxicity screening methods plays a crucial role in the pharmaceutical industry. His contributions help pave the way for safer drug development practices.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…